CLN-049 is a monoclonal antibody commercialized by Cullinan Oncology, with a leading Phase I program in Myelodysplastic Syndrome. According to Globaldata, it is involved in 1 clinical trial, which is ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of CLN-049’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for CLN-049 is expected to reach an annual total of $9 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
CLN-049 is under development for the treatment of relapsed or refractory acute myelocytic leukemia and myelodysplastic syndrome. The drug candidate is a Bi-specific T-cell engager (BiTE) monoclonal antibody acts by targeting fms-like tyrosine kinase 3 (FLT3) and CD3. It is administered through intravenous and subcutaneous route.
Cullinan Oncology Overview
Cullinan Oncology clinical-stage biotechnology company. It focuses on the discovery and development of oncology therapies. Its product pipeline includes CLN-081 for the treatment of non-small cell lung cancer; CLN-619 against pan-cancer; and CLN-049 to treat relapsed and refractory acute myelogenous leukemia (AML), and myelodysplastic syndrome (MDS). Cullinan Oncology’s pipeline also includes drug programs such as CLN-418 for multiple solid tumors; CLN-978 to treat B-cell non-Hodgkin lymphomas; and CLN-617 for treatment of pan-cancer. The company also provides various patient support programs. Cullinan Oncology is headquartered in Cambridge, Massachusetts, the US.
The operating profit of the company was US$144.7 million in FY2022, compared to an operating loss of US$68 million in FY2021. The net profit of the company was US$111.2 million in FY2022, compared to a net loss of US$65.6 million in FY2021.
For a complete picture of CLN-049’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.